SG&A Efficiency Analysis: Comparing Novartis AG and Regeneron Pharmaceuticals, Inc.

SG&A Trends: Novartis vs. Regeneron Over a Decade

__timestampNovartis AGRegeneron Pharmaceuticals, Inc.
Wednesday, January 1, 201414993000000504755000
Thursday, January 1, 201514247000000838526000
Friday, January 1, 2016141920000001177697000
Sunday, January 1, 2017149970000001320433000
Monday, January 1, 2018164710000001556200000
Tuesday, January 1, 2019143690000001834800000
Wednesday, January 1, 2020141970000001346000000
Friday, January 1, 2021148860000001824900000
Saturday, January 1, 2022142530000002115900000
Sunday, January 1, 2023124890000002631300000
Monday, January 1, 2024125660000002954400000
Loading chart...

Igniting the spark of knowledge

SG&A Efficiency: A Tale of Two Giants

In the competitive landscape of pharmaceuticals, understanding operational efficiency is crucial. Over the past decade, Novartis AG and Regeneron Pharmaceuticals, Inc. have showcased contrasting trends in their Selling, General, and Administrative (SG&A) expenses. Novartis, a Swiss multinational, has seen its SG&A expenses fluctuate, peaking in 2018 with a 10% increase from 2014, before declining by 24% in 2023. Meanwhile, Regeneron, an American biotechnology company, has experienced a consistent upward trajectory, with a staggering 421% increase in SG&A expenses from 2014 to 2023. This divergence highlights differing strategic priorities: Novartis appears to be optimizing its operational costs, while Regeneron is investing heavily in growth. As the pharmaceutical industry evolves, these trends offer valuable insights into how companies balance cost management with expansion strategies.

Published by
U.S. Securities and Exchange Commission

Source link
sec.gov

Date published
17 Jan 2025